Search: WFRF:(Gollob Jared) >
A phase II, open-la...
A phase II, open-label, extension study of long-term patisiran treatment in patients with hereditary transthyretin-mediated (hATTR) amyloidosis
-
Coelho, Teresa (author)
-
Adams, David (author)
-
Conceicao, Isabel (author)
-
show more...
-
Waddington-Cruz, Marcia (author)
-
Schmidt, Hartmut H. (author)
-
Buades, Juan (author)
-
Campistol, Josep (author)
-
Berk, John L. (author)
-
Polydefkis, Michael (author)
-
Wang, Jing Jing (author)
-
Chen, Jihong (author)
-
Sweetser, Marianne T. (author)
-
Gollob, Jared (author)
-
- Suhr, Ole B. (author)
- Umeå universitet,Avdelningen för medicin
-
show less...
-
(creator_code:org_t)
- 2020-07-08
- 2020
- English.
-
In: Orphanet Journal of Rare Diseases. - : BioMed Central (BMC). - 1750-1172. ; 15:1
- Related links:
-
https://doi.org/10.1...
-
show more...
-
https://umu.diva-por... (primary) (Raw object)
-
https://ojrd.biomedc...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
show less...
Abstract
Subject headings
Close
- Background: Patisiran, an RNA interference therapeutic, has demonstrated robust reduction of wild-type and mutant transthyretin protein and was able to improve polyneuropathy and quality of life following 18 months of treatment in patients with hereditary transthyretin-mediated (hATTR) amyloidosis.In this 24-month Phase II open-label extension study, we evaluated the effects of patisiran treatment (0.3 mg/kg intravenously every 3 weeks) on safety, serum transthyretin levels, and clinical parameters. Efficacy assessments included modified Neuropathy Impairment Score +7 (mNIS+7) and multiple disease-relevant measures. Cardiac assessments were performed in a pre-specified cardiac subgroup.Results: Twenty-seven patients entered this study, including 12 (44%) with ambulation difficulties due to their neuropathy and 11 (41%) who met criteria for the cardiac subgroup. During treatment, the majority of adverse events were mild/moderate in severity; there were no drug-related adverse events leading to treatment discontinuation. The most common drug-related adverse events were flushing and infusion-related reactions (22% each). Patisiran resulted in rapid, robust (similar to 82%), and sustained reduction of mean transthyretin levels over 24 months. A mean 6.95-point decrease (improvement) in mNIS+7 from baseline was observed at 24 months. Patisiran's impact on mNIS+7 was irrespective of concomitant tafamidis or diflunisal use, sex, or age. Clinical assessments of motor function, autonomic symptoms, disease stage, and quality of life remained stable over 24 months. No significant changes were observed for echocardiographic measures or cardiac biomarkers in the cardiac subgroup. Exploratory analyses demonstrated improvements in nerve-fiber density with corresponding reductions in amyloid burden observed in skin biopsies over 24 months.Conclusions: Long-term treatment with patisiran had an acceptable safety profile and was associated with halting/improvement of polyneuropathy progression in patients with hATTR amyloidosis.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Neurologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Neurology (hsv//eng)
Keyword
- ATTR amyloidosis
- Cardiomyopathy
- Patisiran
- Polyneuropathy
- RNA interference
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
To the university's database
- By the author/editor
-
Coelho, Teresa
-
Adams, David
-
Conceicao, Isabe ...
-
Waddington-Cruz, ...
-
Schmidt, Hartmut ...
-
Buades, Juan
-
show more...
-
Campistol, Josep
-
Berk, John L.
-
Polydefkis, Mich ...
-
Wang, Jing Jing
-
Chen, Jihong
-
Sweetser, Marian ...
-
Gollob, Jared
-
Suhr, Ole B.
-
show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Clinical Medicin ...
-
and Neurology
- Articles in the publication
-
Orphanet Journal ...
- By the university
-
Umeå University